Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effects of Samuraciclib and Elacestrant for Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of breast cancer known as Hormone Receptor-positive (HR+) and Human Epidermal Growth Factor Receptor 2-negative (HER2-) breast cancer. The study is testing a combination of two treatments: Samuraciclib, which is taken as a capsule, and Elacestrant, available in film-coated tablets. The purpose of the study is to find the best dose of these medications when used together and to see how effective they are in treating this type of breast cancer.

The study is divided into two phases. In the first phase, researchers will determine the most suitable dose of the combination treatment. In the second phase, they will assess how well the treatment works in terms of delaying the progression of the disease. Participants will take the medications orally, and their health will be monitored throughout the study to observe any changes in their condition and to check for any side effects.

Participants in this study have breast cancer that has either spread to other parts of the body or is locally advanced, meaning it cannot be removed or treated with radiation to cure it. The study aims to provide valuable information on the effectiveness of the combination of Samuraciclib and Elacestrant in managing this specific type of breast cancer.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the participant will be informed about the trial's purpose and procedures. The study involves testing the combination of two medications: samuraciclib and elacestrant.

    The participant will be required to provide consent to participate in the study, acknowledging understanding of the trial's objectives and potential risks.

  2. Step 2

    Phase 1b: dose finding

    This phase aims to determine the recommended dose for the next phase. Participants will receive samuraciclib and elacestrant orally.

    The dosage will be adjusted to identify the optimal dose that balances effectiveness and safety. Participants will be monitored for any side effects or adverse reactions.

  3. Step 3

    Phase 2: expansion

    In this phase, the effectiveness of the medication combination will be assessed. The focus will be on progression-free survival, which measures the time during and after treatment that the participant lives with the disease without it getting worse.

    Participants will continue to take samuraciclib and elacestrant orally at the dose determined in Phase 1b.

  4. Step 4

    Medication details

    Samuraciclib is administered in capsule form, while elacestrant is available as film-coated tablets in two dosages: 86 mg and 345 mg.

    Both medications are taken orally, and the specific dosage and frequency will be determined by the study team based on the participant's response and tolerance.

  5. Step 5

    Monitoring and assessments

    Throughout the trial, participants will undergo regular assessments to monitor their health and the effectiveness of the treatment.

    These assessments may include blood tests, imaging studies, and other evaluations to track the progression of the disease and any side effects.

  6. Step 6

    End of trial

    The trial is expected to conclude by June 2025. Participants will be informed about the results and any further steps if necessary.

    Upon completion, participants may receive follow-up care as determined by the study team.

Who can join the trial?

8 criteria

  • Must have a confirmed diagnosis of **breast cancer** that has spread or is advanced, and cannot be treated with surgery or radiation to cure it.
  • The cancer must be **ER-positive**, meaning the tumor has at least 10% of cells that react to estrogen, with or without being **PgR-positive** (reacting to progesterone).
  • The cancer must be **HER2-negative**, which means it does not have high levels of a protein called HER2.
  • Must have either measurable disease or bone-only disease with lesions that can be evaluated. If radiation was done on the bone, there must be at least one lesion in an area that wasn't treated with radiation.
  • Must show that the disease has gotten worse while on or within 6 months after the last treatment.
  • Must have taken an **aromatase inhibitor** (a type of hormone therapy) with a **CDK4/6 inhibitor** (a type of cancer treatment) and benefited from it for at least 6 months. If the CDK4/6 inhibitor was stopped early due to side effects, the aromatase inhibitor must have been taken for at least 6 months.
  • Must have a life expectancy of more than 12 weeks.
  • Both males and females can participate.

Who cannot join the trial?

10 criteria

  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients with a history of severe allergic reactions to the study drugs cannot participate.
  • Patients with uncontrolled medical conditions, such as high blood pressure or diabetes, cannot participate.
  • Patients who have received another investigational drug within the last 4 weeks cannot participate.
  • Patients with active infections, such as a cold or flu, cannot participate.
  • Patients with a history of other cancers, except for certain skin cancers, cannot participate.
  • Patients with significant heart problems, such as heart failure, cannot participate.
  • Patients with liver disease, such as hepatitis, cannot participate.
  • Patients with kidney disease, such as chronic kidney disease, cannot participate.
  • Patients who are unable to swallow pills cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Samuraciclib

    is a medication being studied for its potential to treat certain types of breast cancer. It is being tested in combination with another drug to see if it can help stop or slow down the growth of cancer cells in patients with hormone-receptor-positive and HER2-negative breast cancer.

  • Elacestrant

    is another medication involved in this study. It is used to target and block the effects of hormones that can promote the growth of breast cancer cells. In this trial, it is combined with samuraciclib to evaluate if the combination is more effective in treating breast cancer compared to using each drug alone.

What is already known about the treatment

  • Samuraciclib

    Samuraciclib is administered orally and is currently being studied in clinical trials for its potential use in treating breast cancer, specifically in cases that are hormone-receptor-positive and HER2-negative. It is in the investigational stage, with ongoing research to determine its effectiveness and optimal dosing. The medication works by inhibiting certain enzymes that are involved in cell cycle regulation, potentially slowing down or stopping the growth of cancer cells. It is classified as a cyclin-dependent kinase inhibitor.

  • Elacestrant

    Elacestrant is taken orally and is under investigation for its use in treating breast cancer, particularly in patients with hormone-receptor-positive and HER2-negative types. It is currently in clinical trials to evaluate its safety and efficacy. Elacestrant functions by blocking estrogen receptors, which can help reduce the growth of cancer cells that rely on estrogen. It belongs to the class of selective estrogen receptor degraders.

Investigated diseases

Breast Cancer – Breast cancer is a disease where cells in the breast grow uncontrollably, forming a tumor that can often be felt as a lump or seen on an X-ray. It typically begins in the ducts or lobules of the breast and can spread to other parts of the body if not managed. The progression of breast cancer can vary, with some tumors growing slowly and others more rapidly. Hormone receptor status, such as estrogen receptor-positive or negative, can influence the growth and spread of the cancer. The disease can cause changes in breast shape, size, or appearance, and may lead to symptoms like skin dimpling or nipple discharge. Early detection and understanding of the cancer's characteristics are crucial for managing its progression.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase ITrial ID2023-503846-30-00Protocol codeCT7001_003Estimated enrolment68 patientsSponsorCarrick Therapeutics Limited

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.